Literature DB >> 17576983

Health Canada's Progressive Licensing Framework.

Neil Yeates1, David K Lee, Maurica Maher.   

Abstract

Mesh：

Year:  2007        PMID： 17576983      PMCID： PMC1891129          DOI： 10.1503/cmaj.070597

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  6 in total

1.  Progressive drug licensing: an opportunity to achieve transparency and accountability?

Authors:  James M Wright
Journal:  CMAJ       Date:  2007-06-19       Impact factor: 8.262

2.  Progressive licensing needs progressive open debate.

Authors:  Paul C Hébert; Matthew Stanbrook; Barbara Sibbald; Ken Flegel; Noni MacDonald; Amir Attaran
Journal:  CMAJ       Date:  2007-06-19       Impact factor: 8.262

Review 3.  Moving from opacity to transparency in pharmaceutical policy.

Authors:  Irfan Dhalla; Andreas Laupacis
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

4.  Can Health Canada protect Canadians from unsafe drugs?

Authors:  Paul C Hébert; Matthew B Stanbrook; Noni MacDonald; Ken Flegel; Jane Coutts; Stuart MacLeod
Journal:  CMAJ       Date:  2011-04-18       Impact factor: 8.262

Review 5.  Product regulation and the clinical translation of stem cell research.

Authors:  Barbara von Tigerstrom
Journal:  Stem Cell Rev Rep       Date:  2009-03-04       Impact factor: 5.739

6.  Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need.

Authors:  G Hirsch; M Trusheim; E Cobbs; M Bala; S Garner; D Hartman; K Isaacs; M Lumpkin; R Lim; K Oye; E Pezalla; P Saltonstall; H Selker
Journal:  Clin Pharmacol Ther       Date:  2016-10-22       Impact factor: 6.875
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.